World's First In-Utero Stem Cell Therapy for Fetal Spina Bifida Found Safe in Landmark Study

A Breakthrough in Fetal Medicine

Researchers at UC Davis Health have achieved a historic milestone: the world's first in-utero stem cell therapy for spina bifida has proven safe in a Phase 1/2a clinical trial. Results published in The Lancet garnered over 240 upvotes on Hacker News and widespread attention from the medical community.

CuRe Trial Results

The CuRe Trial combined traditional fetal surgery with placenta-derived stem cells administered in utero. Key safety findings include:

No adverse effects linked to stem cell treatment

Zero infections, spinal fluid leaks, or abnormal tissue growth

Complete wound healing in all surgeries

MRI scans showed reversal of hindbrain herniation in all infants

No patients required shunts for hydrocephalus before discharge

Why Spina Bifida Matters

Spina bifida is a congenital condition affecting approximately 1,500 to 2,000 U.S. children annually, caused by incomplete closure of the spinal canal during fetal development. While conventional fetal surgery has improved outcomes, many patients face long-term mobility challenges that this stem cell approach may help address.

What's Next

The trial is now enrolling up to 35 patients with follow-up evaluations through age 6. Principal Investigator Diana Farmer, MD, stated: "Putting stem cells into a growing fetus was a total unknown. We are excited to report great safety." This landmark result opens a promising new chapter in fetal medicine and regenerative therapy.